EDMONTON, Alberta –
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced a fresh lineup of innovative products. Coming soon to patients at Aurora Medical and to consumers at retail stores across the country, the company’s expanded portfolio includes newly developed cultivars, strain-specific gummies and aromatic vapes. Flower products include two original strains from Occo, Aurora’s esteemed breeding program: Pink Diesel ’71 and Moon Berry.
“We’re delighted to unveil the latest additions to our ever-evolving portfolio of products,” says Lana Culley, Vice President of Product Development at Aurora Cannabis. “Our R&D team is focused on developing new products that capture the essence of what our patients and consumers value most – high quality and consistent cannabis in a wide variety of formats. Our spring lineup delivers on that and builds upon our total portfolio of Aurora products.”
Through Aurora’s best-in-class genetics breeding program, backed by extensive consumer research and development, Aurora continues to focus on expanding its portfolio of product offerings, while developing unique cultivars and formats that appeal to a wide variety of patients and consumers.
New products launching this April include:
San Rafael ’71:
Pink Diesel ’71 (3.5g & 14g flower, 3 x 0.5g pre-rolls) – A premium strain crossbred from two of San Rafael ’71’s most popular cultivars, Pink Kush and Driftwood Diesel. The result is a pungent, powerful and 100% original indica with notes of gas, lavender and spice, delivering 24-30% THC. Hang-dried, hand-finished and hand-bottled for an excellent final product.
Moon Berry (3.5g & 14g flower, 3 x 0.5g pre-rolls) – A premium strain with a balanced 1:1 ratio of THC to CBD, Moon Berry has a delightful aroma of berries, cream and lemon. Bred from Aurora Medical’s Vespera and Equiposa cultivars, Moon Berry is a great choice for those looking for a full-flavoured experience with moderate THC and balanced CBD.
Tangerine Dream Cured Resin Gummies (4 x 2.5mg) – Made with strain-specific cured resin from premium dried flower extracted using Aurora’s state-of-the-art hydrocarbon process. These sativa gummies have a sweet citrus, tangerine flavour inspired by the character of the flower.
Greybeard:
DJ Melon Live Resin Diamonds & Sauce (1g) – Named after a unique formulation that combines KISH and AFD live resins, resulting in a melon-y aroma, DJ Melon is 99.9% THCa Diamonds smothered in a sweet terp sauce that evokes light citrus notes with subtle hints of pine.
Pineapple M Live Resin Diamonds & Sauce (1g) – Boasted a rich fuel and pineapple aroma, Pineapple M is 99.9% THCa Diamonds smothered in a sweet and gassy terp sauce. This limited time offer is made with our award-winning hydrocarbon extract process.
Slymer Live Resin Vape (510 – 1g) – Made from 100% pure live resin, Slymer is named for its abundant trichome production and exceptional pine and lemon aroma for a fresh and invigorating true-to-strain experience.
Trufflez Live Resin Vape (510 – 1g) – With an ultra-gassy, savoury and earthy aroma profile, Trufflez is made from 100% pure live resin.
Whistler Cannabis Co.:
Organic BC Rockstar (28g flower) – One of our best-selling strains of all time is now available in a 28g format, for a limited time only. Bred from a cross of Rockstar and Bubba Kush cultivars, BC Rockstar is a hard-hitting indica with earthy and piney notes. Delivering 20-27% THC, this flower is grown in living soil with a small-batch approach.
Daily Special
Mondo Grape XL Vape (510 – 1g) – Delivering big grape flavour, this vape is made with a proprietary resin blend, enhanced with botanical terpenes for a broad-spectrum, full-flavour experience.
The spring product release is set to roll out to patients on Aurora Medical and in adult-use retailers starting in April. Select products are available in certain regions.
About Aurora:
Aurora is opening the world to cannabis, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company’s adult-use brand portfolio includes Aurora Drift, San Rafael ’71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America’s leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn.
Aurora’s common shares trade on the NASDAQ and TSX under the symbol “ACB”.
Forward-looking Information
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include, but are not limited to, statements with respect to product innovation and new products to market, competitive advantages including breeding and genetics and consumer research, and the expected timing for the release of new products in the medical and recreational channels.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management’s estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management’s estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 20, 2022 (the “AIF”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
